ERBB2 and cancer: The molecular classification has not changed and HER2 low cannot be considered a molecular subtype, but it is important to recognize these patients since in the DESTINY-Breast04 clinical trial, trastuzumab deruxtecan (T-DXd) demonstrated that even fewer HER2 receptors on cancer cells may be sufficient for clinical benefit 20,.21